DEVGEN 
By
Regulated information
Zwijnaarde - 8 April 2011 - In accordance with Article 15 §1 first paragraph of the Act of May 2, 2007 on the disclosure of major shareholdings in listed companies, Devgen nv hereby announces two consecutive capital increases for a total of 4,586,794 new shares:
- on 4 April 2011, 4,584,549 new shares have been issued as the result of a private placement,
- on 8 April 2011, 2.245 new shares have been issued as the result of the exercise of warrants by employees of the company.
Information as of 8 April 2011:
Basic data
| Total share capital (EUR) | 1,819,755 |
| Total number of securities conferring voting rights | 24,263,436 |
| Total number of voting rights (the denominator): | 24,263,436 |
| Total number of securities conferring voting rights by category: | N/A |
| Total number of voting rights by category | N/A |
Additional facts
| Total number of convertible bonds conferring voting rights | none |
| Total number of rights, materialized by certificates or not, to subscribe to not yet issued securities which confer voting rights | 1,526,704 |
| Total number of voting rights which result from the exercise of these conversion or subscription rights | 1,526,704 |
| Total number of shares without voting rights | none |
According to Article 14 of the Act of May 2, 2007 on the disclosure of major shareholdings in listed companies, Devgen nv hereby makes public that it received the following notification of shareholding:
Gimv NV and its daughter company Adviesbeheer Gimv Venture Capital 2010 NV have, in concert with Biotech Fonds Vlaanderen (with as the ultimate shareholder The Flemish Region) passed the threshold of 5% on April 4, 2011.
| Denominator | Number of voting rights before the transaction | Number of voting rights after the transaction | % voting rights | |
| Gimv NV | 24,263,436 | 0 | 448,718 | 1.85 |
| Adviesbeheer Gimv Venture Capital 2010 NV | 64,103 | 0.26 | ||
| Biotech Fonds Vlaanderen NV | 1,025,641 | 4.23 | ||
| Total of in concert acting parties | 1,538,462 | 6.34 |
About Devgen nv
Devgen's mission is to deliver the next green revolution in rice to growers that cultivate 60m ha rice in India and S.E. Asia.
Devgen uses advanced biotechnology and molecular breeding technology to develop the Next Generation Hybrid Rice (NGHR) and crop protection solutions with a superior environmental profile:
§ Devgen developed the next generation of hybrid rice, improving yield, seed productivity, grain quality, and tolerance to biotic and abiotic stress factors. Devgen strongly believes that this hybrid rice technology has the potential to drive the accelerated conversion of varietal rice to hybrid rice.
§ Anticipating the need to increase insect resistance and drought/heat tolerance in rice to a level that is beyond what can be achieved with classical breeding, Devgen created a portfolio of biotech traits using own technology as well as in-licensed technologies.
§ Devgen established an integrated seed business in India and Southeast Asia through which its rice crops and technologies reach the market.
§ In India, Devgen complemented its hybrid rice business with geographically and seasonally complementary crops: hybrid sorghum, pearl millet and sunflower.
§ In its Crop Protection unit, Devgen develops a novel nematicide, an agro-chemical product that protects crops from damage by parasitic nematodes. This product is sold in Turkey and in the US.
§ Devgen innovates in crop protection research and environment induced stress tolerance for its own crops and providing technology to corporate partners.
Incorporated in 1997, Devgen has offices in Ghent (Belgium), and has subsidiaries in Singapore, Hyderabad (India), Yogyakarta (Indonesia), General Santos (Philippines) and Delaware (US), totaling about 280 employees.
For more information please contact:
| Thierry Bogaert, CEO | Wim Goemaere, CFO |
| Tel. +32 9 324 24 24 | Tel. +32 9 324 24 24 |
| Thierry.Bogaert@devgen.com: mailto:Thierry.Bogaert@devgen.com | Wim.Goemaere@devgen.com |
Or visit: www.devgen.com:
http://www.devgen.com/
This press release may contain forward-looking statements containing the words "anticipates", "expects" , "intends", "plans", "estimates", "may" and "continues" as well as similar expressions. Such forward looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, performance or achievements of Devgen to be materially different from any future results or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: agricultural risks and difficulties, including weather factors, diseases and pests, the costs and requirements of regulatory compliance and the speed with which approvals are received; public acceptance of biotechnology products; political, economic and social developments in countries where Devgen operates and other risks and factors detailed in the company's most recent annual report.
These forward looking statements speak only as of the date of publication of this document. Devgen disclaims any obligation to update such forward looking statements in this document to reflect any change in its expectations, conditions or circumstances on which such statement is based, unless required by law or regulation. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any securities issued by Devgen NV.
http://hugin.info/135721/R/1504902/439841.pdf
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Devgen via Thomson Reuters ONE
